MedTrace Logo

Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)

NCT04379310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2020-06-05

No results posted yet for this study

Summary

Investigators will recruit patients diagnosed with COVID-19 pneumonia between March 11th, 2020 and April 15th, 2020 in emergency, internal medicine and cardiology outpatient clinics, retrospectively and analyze their clinical and demographic features on admission in regard to their medications used for chronic diseases regularly.

Conditions

Interventions

DRUG

ACE Inhibitors and Calcium Channel Blockers

effect of drugs on patients with covid-19 pneumonia

Sponsors & Collaborators

  • Istanbul Nisantasi University

    lead OTHER

Principal Investigators

  • Hasan Haciosman · academic staff, MD

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-05-05
Completion
2020-05-08

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04379310 on ClinicalTrials.gov